Sanjay Phogat

Immunology and Microbiology · Life Sciences

39h-index9.3kcitations130works2.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(89), Immune Cell Function and Interaction(31), Monoclonal and Polyclonal Antibodies Research(27), HIV/AIDS drug development and treatment(20), Immunotherapy and Immune Responses(19)

Publications128 total

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand
Open Forum Infectious Diseases·2025Open Access
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial
PLOS Global Public Health·2024Open Access
The effect of the mechanodynamic lung environment on fibroblast phenotype via the Flexcell
BMC Pulmonary Medicine·2024· 3 citedOpen Access
NA
immuneACCESS·2024
Reverse development of vaccines against antimicrobial-resistant pathogens
npj Vaccines·2024· 7 citedOpen Access
Protein Language Model for Prediction of Subcellular Localization of Protein Sequences from Gram-negative bacteria (ProtLM.SCL)
2022· 4 citedOpen Access
T-cell receptor specific protein language model for prediction and interpretation of epitope binding (ProtLM.TCR)
2022· 4 citedOpen Access
Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics
Pharmacology & Therapeutics·2022· 42 citedOpen Access
TMQuery: a database of precomputed template modeling scores for assessment of protein structural similarity
Bioinformatics·2022
Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies
Frontiers in Immunology·2021· 156 citedOpen Access
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
New England Journal of Medicine·2021· 221 citedOpen Access
Vaccinology in the post−COVID-19 era
Proceedings of the National Academy of Sciences·2021· 90 citedOpen Access
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
PLoS Pathogens·2020· 15 citedOpen Access
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
PLoS Medicine·2020· 48 citedOpen Access
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
Scientific Reports·2020· 24 citedOpen Access
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
The Lancet HIV·2020· 46 citedOpen Access
HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions
JCI Insight·2020· 27 citedOpen Access
Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector
Scientific Reports·2019· 11 citedOpen Access
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
PLoS Pathogens·2019· 24 citedOpen Access
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
Journal of Virology·2019· 23 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

David C. Montefiori(19), Georgia D. Tomaras(17), Guido Ferrari(10), Nelson L. Michael(10), Dennis R. Burton(9), Richard T. Wyatt(8), John R. Mascola(8), Susan W. Barnett(8), Faruk Sinangil(7), Michael S. Seaman(7), Xiaoying Shen(7), Nicole L. Yates(7), Marie Pancera(6), Peter D. Kwong(6), M. Juliana McElrath(6), Kathryn E. Foulds(6), Jérôme H. Kim(6), Merlin L. Robb(6), James Tartaglia(6), Giuseppe Pantaleo(6)